logo
Plus   Neg
Share
Email

Halozyme: Genentech Reports Positive Outcome From Phase III Study Using ENHANZE

Halozyme Therapeutics, Inc. (HALO) said the phase III FeDeriCa trial, a global study conducted by Genentech using combination of pertuzumab and trastuzumab using Halozyme's ENHANZE drug delivery technology, met its primary endpoint. Halozyme said the results of the study is an important development for the ENHANZE technology.

Helen Torley, CEO, said: "This is the first study to combine two therapeutic antibodies as a single fixed-dose subcutaneous formulation utilizing our ENHANZE technology, thereby providing patients with HER2-positive breast cancer the possibility of a faster treatment option."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Department of Transportation says it received lesser number of complaints from consumers about airline services in August. In August, DOT received 1,712 complaints about airline service from consumers, down 1.0% from the total of 1,730 filed in August 2018 and down 8.7% from the 1,875 received... Shares of Netflix Inc. (NFLX) jumped 7% in extended trading session Wednesday after the online-video streaming giant said it added more subscribers in the third quarter after a disappointing previous quarter. The company's third-quarter earnings topped Wall Street estimates, as revenues surged 31%. Netflix... Alcoa Corp. (AA), the largest producer of aluminum in the US, Wednesday posted a wider-than-expected loss for the third quarter, reflecting a drop in revenues as well as one-time charges related to two smelters in Spain. The company also announced a "portfolio review" of its smelting and refining capacity...
RELATED NEWS
Follow RTT
>